ROMA (ITALPRESS) – Alexion, AstraZeneca Rare Disease, has announced the approval in the European Union (EU) of gefurulimab as an additional therapy to the standard of care for the treatment of mystenia gravis generalized (gMG) in adults positive to antibodies-receptor of acetylcholine (AChR). Gefurulimab is a C5 inhibitor made up of a double-linked nanobody, and allows undercutaneous self-administration once a week by autoimator. The approval by the European Commission follows the positive opinion of the Human Use Medicines Committee (CHMP) of the European Medicines Agency (EMA) and is based on the positive results of the Phase III PREVAIL record. The study data showed that gefurulimab reached the primary endpoint, demonstrating an improvement compared to the base of the total score of the Myasthenia Gravis Activities of Daily Living (MG-ADL) per week 26 compared to the placebo. A clinically significant improvement has been observed since the first week and has been maintained until the week 26.GMG is a rare autoimmune disease characterized by a reduction of muscle function and severe muscle weakness. It is estimated that some 82,500 people in the five main European countries (Germany, France, the United Kingdom, Italy and Spain) live with a diagnosis of gMG and that approximately 66,000 are positive to anti-AChR antibodies. «The clinical management of mystenia gravis generalized is complex: symptoms, severity and path of the disease can vary considerably from patient to patient, and an early and lasting control of the pathology is fundamental to improve clinical outcomes», said Tobias Ruck, Director of the Department of Neurology at BG University Hospital Bergmannsheil Bochum of Ruhr-University Bochum and experimenter of the study. “The Phase III PREVAIL study demonstrated the ability of gefurulimab to ensure rapid and lasting control of the disease, which can be observed from the first week and maintained up to a year, with the advantage of weekly subcutaneous self-administration. This approval represents a new important therapeutic option for doctors and patients in the EU, offering an effective and practical approach to managing this serious chronic rare disease”. “Mixia gravis generalized is a disease characterized by peculiar manifestations, uncertainty, limitations and often invisibleness of symptoms”, said Lutgarde Allard, President of the European Myasthenia Gravis Association (EuMGFA). “For people who live with this rare disease throughout Europe, the approval of this new drug means greater therapeutic possibilities, more practicality and the prospect of recovering independence in everyday life. This news represents much more than scientific progress: it offers hope and shows that the needs of our community are heard”. “The approval of gefurulimab in Europe is an important milestone for the gMG patient community, introducing a therapy that combines the effectiveness and safety of C5 inhibition with the flexibility of a weekly subcutaneous self-administrated administration,” said Marc Dunoyer, Chief Executive Officer of Alexion. “This innovative double-linked nanobody testifies to Alexion’s pioneering heritage in complement science and constant commitment to the development of differentiated therapies for people suffering from rare diseases.” Gefurulimab was generally well tolerated and its safety profile was consistent with that observed in previous studies on C5 eculizumab and ravulizumab inhibitors in gMG. The data of the PREVAIL study were presented during the scientific session of the MyastheniaGravis Foundation of America (MGFA) at the annual congress 2025 of the American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) and published in JAMA Neurology magazine. Gefurulimab is approved in the United States, Japan and other countries for the treatment of specific adult populations affected by gMG. Applications for authorization based on the results of the PREVAIL study are currently being evaluated in China and other countries.-photo Ipa Agency – (ITALPRESS).





